title: [Distant metastasis after irradiation alone in carcinoma of the uterine cervix--the patterns and results].
abstract: From 1988 to May, 1992, there were 286 patients with pathology-proved carcinoma of the uterine cervix referred to Chang Gung Memorial Hospital, Kaohsiung to receive definite radiotherapy. Sixty-one (21%) patients were found to develop distant metastasis after radiotherapy for at least 2 years follow-up. By FIGO stage, the incidence of distant metastasis was as follows: I :2/39, II a:1/19, II b:20/118, III :34/101, IV a: 4/9. Eighty-five percent patients (52/61) began to develop distant metastasis within the first 2 years after radiotherapy. Twenty-three patients developed single organ metastasis, and 38 patients developed multiple organ metastasis. Lymph nodes (38 patients), lung (28 patients), bone (27 patients), and abdomen (20 patients) were the common sites of distant metastasis. Lymph nodes metastasis occurred most often at supraclavicular lymph nodes (15 patients), para-aortic lymph nodes (18 patients), and inguinal lymph nodes (5 patients). Spine (23 patients), especially the lumbar spine (20 patients) was the most common site of bony metastasis. Abdominal metastasis occurred in abdominal cavity (15 patients) or liver (5 patients). The incidence of metastasis within the first two years after radiotherapy was lung: 75% (21/28), bone: 62% (18/29), left supraclavicular lymph nodes: 60% (9/15), para-aortic lymph nodes: 72% (13/18), intra-abdominal cavity: 86% (13/15), liver: 66% (2/3), brain: 0% (0/4). The 2-year actuarial survival rate for the 61 patients after developing distant metastasis was 14%, with a median survival time of 6.4 months. There was no significant difference in survival when comparing patients with single organ metastasis and with multiple organ metastasis (p > 0.05), or patients with distant metastasis alone and with distant metastasis combined with local recurrence (p > 0.05). Otherwise, after distant metastasis twenty-three patients receiving chemotherapy or radiotherapy had a significantly higher 2-year survival rate than 38 patients receiving supportive care only after distant metastasis (34% vs. 2.4%, p < 0.05).
authors.affiliation: Department of Radiation Oncology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, R.O.C.
authors.forename: F M
authors.initials: FM
authors.lastname: Fang
authors.forename: S W
authors.initials: SW
authors.lastname: Leung
authors.forename: C C
authors.initials: CC
authors.lastname: Changchien
authors.forename: C J
authors.initials: CJ
authors.lastname: Wang
authors.forename: H J
authors.initials: HJ
authors.lastname: Chen
authors.forename: L M
authors.initials: LM
authors.lastname: Sun
authors.forename: H C
authors.initials: HC
authors.lastname: Hsu
mesh_terms: D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D009362:Neoplasm Metastasis; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000532:radiotherapy*